Abstract Number: 616 • 2013 ACR/ARHP Annual Meeting
Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of-Death Analysis In France
Background/Purpose: The overall mortality rate of Systemic Lupus Erythematosus (SLE) has improved significantly over the past 50 years but is still high as compared with…Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…Abstract Number: 20 • 2013 ACR/ARHP Annual Meeting
Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus
Background/Purpose: Anti-phospholipid (aPL) antibodies are associated with development of venous thrombosis and stroke in the autoimmune disease systemic lupus erythematosus (SLE). The underlying mechanism for…Abstract Number: 1983 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues
Background/Purpose: When serum is hyperuricemic, so too are all interstitial fluids other than CSF and sweat. Anecdotally, urate crystals deposit as grossly visible tophi in…Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…Abstract Number: 584 • 2013 ACR/ARHP Annual Meeting
The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular diseases (CVD) are one of major causes of morbidity and mortality in SLE patients. Traditional cardiovascular risk factors and disease intrinsic factors contribute…Abstract Number: 364 • 2013 ACR/ARHP Annual Meeting
Hyperuricemia As a Risk Factor for Cardiovascular Disease in Patients With Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular disease (CVD). There is growing evidence that serum uric acid plays an important…Abstract Number: 2898 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis In Systemic Lupus Erythematosus (SLE) and Controls, -An Analysis Of SLE Subgroups
Background/Purpose: Atherosclerosis is often assumed to be the main underlying cause of premature vascular events (VE) among patients with systemic lupus erythematosus (SLE) and accelerated…Abstract Number: 1986 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study
Background/Purpose: Gout patients have an increased risk of myocardial infarction (MI). Since atherosclerosis and plaque rupture are inflammatory processes, anti-inflammatory gout medications might also reduce…Abstract Number: 1036 • 2013 ACR/ARHP Annual Meeting
The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study
Background/Purpose: Psoriasis (PsC) and psoriatic arthritis (PsA) represent common, lifelong inflammatory diseases of the skin and joints (respectively) that are associated with substantial cardiovascular and…Abstract Number: 569 • 2013 ACR/ARHP Annual Meeting
Hydroxycholorquine Is Cardioprotective In Neonatal Rat Cardiomyocytes Exposed To Simulated Myocardial Ischaemic/Reperfusion Injury.-An Effect Mediated Through ERK Phosphorylation
Background/Purpose: A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury…Abstract Number: 372 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Intensively Treated Rheumatoid Arthritis: Comparison To An Osteoarthritis Population. First Prospective Analysis Of The ACT-CVD Cohort
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. This association is thought to be due to the chronic inflammatory disease…Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting
The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…Abstract Number: 959 • 2013 ACR/ARHP Annual Meeting
Interleukin 10 Negatively Correlates With Glycoprotein VI-Related Platelet Activation In Rheumatoid Arthritis (RA): A Novel Potential Target Of Cardiovascular Morbidity In RA
Background/Purpose: Patients with rheumatoid arthritis (RA) die prematurely of cardiovascular disease (CVD). Platelet mediated thrombosis is a major cause of CVD. Platelets amplify inflammation in RA via the collagen receptor,…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 38
- Next Page »